Diabetes is a leading cause of cardiovascular and kidney disease, and novel therapies to
reduce these adverse diabetes outcomes are urgently required. Allopurinol, a uric acid …

Objectives Elevated uric acid (UA) is common in diabetes and is implicated in the
pathogenesis of chronic kidney disease (CKD). Lowering UA with allopurinol may delay …

Aim To assess the association between allopurinol and mortality and cardiovascular
outcomes in an allopurinol‐treated diabetes cohort. Materials and Methods We conducted a …

Background Few studies, if any, have examined cardiovascular outcomes in patients with
diabetes and gout. Both diabetes and gout are risk factors for cardiovascular disease. The …

The role of long-term effects of allopurinol on cardiovascular outcomes and all-cause
mortality in diabetes I read with interest the recently published study in I Diabetes, Obesity …

Background Gout gives rise to increased risk of cardiovascular events. Gout attacks can be
effectively prevented with urate lowering drugs, and allopurinol potentially reduces …

Objective There has been growing interest in the potential role for allopurinol to reduce
cardiovascular events in people with diabetes. While adherence to allopurinol is poor in …

Background: Two recent randomized clinical trials of escalating doses of allopurinol for the
progression of chronic kidney disease (CKD) reported no benefits but potentially increased …

Effect of Allopurinol in Chronic Kidney Disease Progression... : Clinical Journal of the
American Society of Nephrology Effect of Allopurinol in Chronic Kidney Disease …

Introduction Previous studies have shown an association between gout and/or
hyperuricemia and a subsequent increase in cardiovascular disease (CVD) outcomes …